Icariside II induces rapid phosphorylation of endothelial nitric oxide synthase via multiple signaling pathways

Wenpeng Song¹,²,³,⁴*, Yiming Yuan¹,²,³*, Xiaohui Tan¹,²,³, Yangyang Gu¹,⁵, Jianyu Zeng⁴, Weidong Song¹,²,³, Zhongcheng Xin¹,²,³, Dong Fang¹,²,³ and Ruili Guan¹,²,³

¹ Department of Urology, Peking University First Hospital, Beijing, China
² Institute of Urology, Peking University, Beijing, China
³ Beijing Key Laboratory of Urogenital Diseases (male) Molecular Diagnosis and Treatment Center, Beijing, China
⁴ Department of Dental Implant Center, Beijing Stomatological Hospital, School of Stomatology, Capital Medical University, Beijing, China
⁵ Department of Radiation Medicine, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

* These authors contributed equally to this work.

ABSTRACT

Icariside II, as a favonoid compound derived from epimedium, has been proved to involved in a variety of biological and pharmacological effects such as anti-inflammatory, anti-osteoporosis, anti-oxidation, anti-aging, and anti-cancer but its mechanism is unclear, especially in terms of its effect on post-transcriptional modification of endothelial nitric oxide synthase (eNOS). Phosphorylation of eNOS plays an important role in the synthesis of nitric oxide in endothelial cells, which is closely related to erectile dysfunction, atherosclerosis, Alzheimer’s disease, and other diseases. Our study aims to investigate the effect and mechanism of Icariside II on the rapid phosphorylation of eNOS. In this study, human umbilical vein endothelial cells (HUVECs) were stimulated with Icariside II in the presence or absence of multiple inhibitors (1 µM), including LY294002 (PI3K-inhibitor), MK-2206 (AKT-inhibitor), Bisindolylmaleimide X (AMPK-inhibitor), H-89 (CaMKII-inhibitor), KN-62 (PKA-inhibitor), Dorsomorphin (PKC-inhibitor). The proliferation of HUVECs was assessed using cell counting kit-8 (CCK-8). The release of nitric oxide (NO) within HUVECs was detected via fluorescence probe (DAF-FM). Western blot was used to examine the effect of Icariside II on the expression of eNOS, phosphorylation of eNOS, and common signaling pathways proteins. In this study, Icariside II was found to promote the cell proliferation and rapid NO release in HUVECs. The phosphorylation of eNOS-Ser1177 was significantly increased after Icariside II stimulation and reached a peak at 10 min (p < 0.05). Meanwhile, the phosphorylation of eNOS-Thr495 was significantly decreased after 45 min of stimulation (p < 0.05). Following the intervention with multiple inhibitors, it was found that MK-2206 (AKT inhibitor), LY294002 (PI3K inhibitor), KN-62 (AMPK inhibitor), and Bisindolylmaleimide X (PKC inhibitor) could significantly inhibit the phosphorylation of eNOS-Ser1177 caused by Icariside II (p < 0.05), while MK-2206, LY294002, and Bisindolylmaleimide X reversed the alleviated phosphorylation of eNOS-Thr495. We concluded that Icariside can regulate
rapid phosphorylation of eNOS-Ser1177 and eNOS-Thr495 via multiple signaling pathways, resulting in the up-regulation of eNOS and the increased release of NO.

Subjects Biochemistry, Cell Biology, Molecular Biology

Keywords Phosphorylation, Icariside II, Nitric oxide, Endothelial nitric oxide synthase, Flavonoids

INTRODUCTION

The endothelium consists of a single layer of specialized cells (endothelial cells) that form the interface between the vascular lumen and smooth muscle cells (Cyr, Huckaby & Zuckerbraun, 2020). In the past, the vascular endothelium was thought to function only as a mechanical barrier. However, it has been determined that the endothelium is a tissue that regulates vascular tone, cell growth, and interactions between blood cells and vessel walls (Bhang et al., 2018; Godo et al., 2016). It also synthesizes various growth factors and vasoactive substances, and responds to the physical and chemical signals (Signorello et al., 2011; Cheng et al., 2019; Garcia et al., 2017; Busse & Fleming, 1998). Endothelial cells are remarkably plastic according to their environment, which regulates specific organ development and maintains normal organ homeostasis by producing tissue-specific secretions (Song et al., 2021; Rafii et al., 1995; Raynaud et al., 2013). Meanwhile, endothelial cells, in turn, share a common set of functions, including hemostasis, maintenance of vascular permeability, mediation of acute and chronic immune responses to various injuries, and control of vascular tone (Cyr, Huckaby & Zuckerbraun, 2020). Endothelial dysfunction is characterized by reduced nitric oxide (NO) synthesis and NO sensitivity since NO produced by endothelial cells is a pivotal regulator of endothelial function in balance (Donato et al., 2011). NO is a strong vasodilator and anti-inflammatory signaling molecule, which plays a key role in maintaining vasodilator and vasoconstriction, inhibiting smooth muscle cell migration and proliferation, holding the balance between fibrinolysis and thrombosis, and regulating adhesion and aggregation of platelet (Shi & Vanhoutte, 2017; Popyhova et al., 2020; Konukoglu & Uzun, 2017; Heeringa et al., 2006; Jones et al., 1999). NO is also able to promote angiogenesis by up-regulating the levels of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor-2 (VEGFR-2) in vivo and in vitro (Milkiewicz et al., 2005; Hebert, Siavash & Sauk, 2005).

In vivo, endothelial cells can regulate NO synthesis by activating endothelial nitric oxide synthase (eNOS). eNOS is mainly regulated by protein interaction and multi-site phosphorylation, in which the phosphorylation state of the enzyme-specific serine, threonine, and tyrosine residues significantly affects eNOS activity (Kolluru, Siamwala & Chatterjee, 2010). So far, several phosphorylation residues have been proved to be related to eNOS activity, including Ser113, Thr495, Ser615, Ser633, and Ser1177. The most thoroughly studied residues are activation of eNOS-Ser1177 and inhibition of eNOS-Thr495 (Chen et al., 1999; Heiss & Dirsch, 2014). Although a large number of studies on eNOS phosphorylation have been published in recent decades, the specific molecular mechanisms have not been fully understood. Multiple protein kinases, including
AMPK, CaMKII, PKA, PKC, PI3K, ERK, CHK1, and CDK5, have been indicated to constitute the complex regulatory network of eNOS phosphorylation (Heiss & Dirsch, 2014; Wu et al., 2022; Lee et al., 2021; Lee et al., 2018; Xing et al., 2015). Changes in the phosphorylation status of eNOS have an impact on a large number of disease processes including atherosclerosis, hyperhomocysteine, myocardial infarction, reperfusion injury, cerebral ischemia, and erectile dysfunction (Kolluru, Siamwala & Chatterjee, 2010). Overall, the regulation of eNOS phosphorylation is of great significance for the understanding of endothelial dysfunction.

Epimedium is traditional herbal medicine and functional food commonly used in Asia, which can be used to treat and prevent various diseases such as erectile dysfunction, osteoporosis, and depression (He, Wang & Shi, 2020). Icariin and Icariside II derived from epimedium belong to flavonoids and have a variety of biological and pharmacological effects such as anti-inflammatory, anti-osteoporosis, anti-oxidation, anti-aging, and anti-cancer (Xu et al., 2021; Liu et al., 2011; Khan et al., 2015). Liu et al. (2011) found that Icariside II can up-regulate eNOS expression and improve vascular endothelial function by activating EGF/EGFR signaling pathway in porcine arterial endothelial cells. This positive effect of Icariside II was also found in the human umbilical vein endothelial cells (HUVECs) (Tan et al., 2021). Another study indicated that Icariside II is able to promote the proliferation of cavernous endothelial cells and eNOS-Ser1177 phosphorylation by up-regulating ERK1/2 and AKT signaling pathways, alleviating the endothelial cell damage caused by high glucose conditions (Li et al., 2015). However, the effect of Icariside II on rapid phosphorylation of eNOS in endothelial cells has not been fully investigated. In this study, we investigated the rapid regulation of Icariside II on common phosphorylation residues of eNOS and explored its potential mechanisms.

**MATERIALS & METHODS**

**Cells culture**

HUVECs (Catalog #8000; ScienCell, Carlsbad, CA, USA) were purchased from ScienCell Research Laboratories and cultured in endothelial cell medium (ECM, Catalog #1001; ScienCell, Carlsbad, CA, USA), supplemented with 5% fetal bovine serum (FBS, Catalog #0025; ScienCell, Carlsbad, CA, USA), 1% endothelial cell growth supplement (Catalog #1052; ScienCell, Carlsbad, CA, USA), 100 U/ml of penicillin and 100 μg/ml streptomycin solution (Catalog #0503; ScienCell, Carlsbad, CA, USA). HUVECs were incubated at 37 °C with an atmosphere of 5% CO₂ in the humidified incubator (Forma 3110; ThermoFisher Scientific, Lincoln, NE, USA) and passages 3–5 were served for subsequent experiments.

HUVECs were serum-starved in ECM without fetal bovine serum for 4 h before treatment of Icariside II and inhibitors were added. Cells were treated for 0.5, 1, 3, 5, 10, 15, 30, 45 or 60 min with 10⁻⁵, 10⁻⁶, 10⁻⁷, 10⁻⁸ or 10⁻⁹ M Icariside II with or without addition of the PI3K inhibitor LY294002 (1 mM; Catalog #HY-10108; MedChemExpress, NJ, USA), AKT inhibitor MK-2206 (1 mM; Catalog #HY-10358; MedChemExpress), AMPK inhibitor Dorsomorphin (1 mM; Catalog #HY-13418; MedChemExpress), CaMKII inhibitor KN-62 (1 mM; Catalog #HY-13290; MedChemExpress), PKA inhibitor H-89 (1 mM; Catalog #
Table 1  Inhibitors applied in this study.

| Target kinases | Inhibitors          |
|---------------|---------------------|
| AKT           | MK-2206             |
| PI3K          | LY294002            |
| AMPK          | Dorsomorphin        |
| CaMKII        | KN-62               |
| PKA           | H-89                |
| PKC           | Bisindolylmaleimide X |

Notes.
AKT, Protein kinase B; PI3K, Phosphatidylinositol-3-kinase; AMPK, AMP-activated protein kinase; CaMKII, Calcium-CaM-dependent protein kinase II; PKA, Protein kinase A; PKC, Protein kinase C.

HY-15979A; MedChemExpress) or PKC inhibitor Bisindolylmaleimide X (1 mM; Catalog #HY-108136A, MedChemExpress) (Table 1).

**Western blot**

After being stimulated with Icariside II and inhibitors, HUVECs were washed with cold PBS (Catalog #SH30256.01; Hyclone, UT, USA). Total protein was extracted from the cells using lysis buffer containing RIPA (Strong) (#KGP702; Keygen Biotech, Nanjing, China), 1 mM Phenylmethylsulfonyl fluoride (Catalog #KGP610; Keygen Biotech), 1X protease inhibitor (Catalog #KGP603; Keygen Biotech) and 1X Phosphatase inhibitor (Catalog #KGP602; Keygen Biotech). Then the lysates were boiled with 5X SDS-PAGE loading buffer (Catalog #P1040, Solarbio, Beijing, China) for 8 min.

The samples containing 20 µg of protein were electrophoresed in 10% polyacrylamide gel and transferred to a polyvinylidene fluoride membrane. After being blocked for 1 h at room temperature, the membrane was incubated at 4 °C overnight with primary antibodies to p-eNOSabhser1177 (1:300; Catalog #9571; Cell Signaling Technology, Danvers, USA), p-eNOSabhser113 (1:300; Catalog #9574; Cell Signaling Technology), p-AMPKαabhser172 (1:300; Catalog #9375; Cell Signaling Technology), p-AKTabhser473 (1:1000; Catalog #4060; Cell Signaling Technology), p-PKCα/βabhThr638/641 (1:300; Catalog #9375; Cell Signaling Technology), p-AMPKαabhThr172 (1:300; Catalog #2535; Cell Signaling Technology), eNOS (1:300; Catalog #A1548; ABclonal, Woburn, MA, USA) and β-Actin (1:20000; Catalog #10205-2-AP; Proteintech, Rosemont, IL, USA).

After incubated with secondary antibodies, the images of membranes’ signals were obtained by using the Syngene G-Box imaging system (Syngene, Cambridge, UK) via ECL Plus Western Blotting Substrate (Catalog #32132; ThermoFisher Scientific).

**Nitric oxide release measurement**

According to the manufacturer’s protocol, HUVECs were seeded into 96-well plates. At the confluence of 80%, cells were treated with 5 µM NO diacetate 3-Amino,4-aminomethyl-2′, 7′-difluorescein (DAF-FM DA; Catalog #s0019; Beyotime Biotech, Shanghai, China) for 30 min in serum-free medium, followed by drug stimulating with Icariside II for 0–60 min at 37 °C. Control groups were added with an equal volume of serum-free medium.
After washing 3 times with PBS, the fluorescence images were collected by fluorescence microscope with excitation at 495 nM and emission at 515 nM (DMI 6000B, Leica Microsystems, Nussloch, Germany). Fluorescence images were analyzed with ImagePro Plus software (version 6.0, Media Cybernetics Inc, Bethesda, MD, USA) for calculating the mean density.

**Cell proliferation and cytotoxicity assay**

Cell Counting Kit-8 (Catalog #CK04; Dojindo Molecular Technologies, Kumamoto, Japan) and the manufacturer’s protocol were applied for cell proliferation and cytotoxicity assay. After being dispensed in 96-well plates for 12 h, HUVECs were treated with Icariside II in various concentrations (0, $10^{-5}$, $10^{-6}$, and $10^{-7}$ M) for 24 and 48 h. After two washes with ECM, 10 µL CCK-8 solution was added to each well and incubated for 1 h in the incubator. Then, the microplate reader (Catalog #51118170; Thermo Fisher Scientific) was performed to measure the absorbance of each well at 450 nm.

**Statistical analysis**

All experiments were repeated at least three times. All data were analyzed using GraphPad Prism, version 9.0 (GraphPad Software, San Diego, CA, USA) and shown as mean ± standard error of the mean (SEM). One-way ANOVA analysis was used for comparison between different groups. Statistical significance was considered when $P$-values were less than 0.05.

**RESULTS**

**Icariside II promoted the proliferation of HUVECs**

To study the effect of Icariside II on the proliferation of HUVECs, a stimulation of Icariside II for 24 and 48 h was used, showing that the proliferation of HUVECs was significantly promoted at the concentration of $10^{-6}$ and $10^{-7}$ M. In contrast, $10^{-5}$ M of Icariside II showed a significant detraction effect (Figs. 1A, 1B). Therefore, Icariside II with a concentration below $10^{-5}$ was used for subsequent assays.

**Icariside II rapidly increased NO release**

In this study, the NO probe (DAF-FM DA) was adopted to detect the effect of Icariside II ($10^{-6}$M) on NO release. NO release of HUVECs significantly increased after Icariside II was stimulated for 5 min. Within one hour, the mean signals increased gradually with the stimulation time, which indicated that Icariside II could up-regulate NO release of HUVECs rapidly (Figs. 2A, 2B).

**Icariside II stimulation did not alter total eNOS expression**

To investigate the effect of Icariside II on the expression of total eNOS, Icariside II ($10^{-6}$ M) was used to stimulate HUVECs for 0, 5, 10, 15, 30, and 60 min. No significant changes were identified in Icariside II-treated groups compared with controls, suggesting that Icariside II did not affect the total eNOS expression of HUVECs within 60 min. (Figs. 3A, 3B).
Figure 1  Effect of Icariside II on the proliferation of HUVECs. CCK8 kit was used to detect the proliferation of HUVECs at different concentrations of Icariside II (10^{-5} M, 10^{-6} M, 10^{-7} M). (One-way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, Icariside II treated for 24 h vs NC, # p < 0.05, ## p < 0.01, ### p < 0.001, Icariside II treated for 48 h vs NC). Results are expressed as the mean ± SEM analyzed from three independent experiments.

Full-size DOI: 10.7717/peerj.14192/fig-1

Figure 2  Effect of Icariside II stimulation on NO release. (A) HUVECs were stimulated with Icariside II (1*10^{-6} M) for 5, 15, 30, 45, and 60 min and loaded with DAF-FM DA. Fluorescence imaging was performed to detect intracellular NO release. (B) Quantitative analysis of NO release. (One-way ANOVA: * p < 0.05, ** p < 0.01, *** p < 0.001, experimental groups vs NC). Results are shown as one representative image and as the mean ± SEM of quantified data from three independent experiments.

Full-size DOI: 10.7717/peerj.14192/fig-2
**Figure 3  Effect of Icariside II on total eNOS expression.** HUVECs were stimulated with Icariside II (1 µM) for 5, 15, 30, 45, and 60 min. (A) Western blot analysis of the expression of total eNOS. (B) Quantitative analysis of total eNOS expression. (One-way ANOVA: *p < 0.05, **p < 0.01, ***p < 0.001, experimental groups vs NC). Results are shown as one representative blot and as the mean ± SEM of quantified data from three independent experiments.

Song et al. (2022), PeerJ, DOI 10.7717/peerj.14192/fig-3

**Icariside II rapidly induced eNOS-Ser1177 phosphorylation of HUVECs via PI3K/AKT, AMPK, and PKC signaling pathway**

To further clarify the experimental concentration of Icariside II in subsequent experiments, HUVECs were treated with different concentrations of Icariside II (10^{-5} M, 10^{-6} M, 10^{-7} M, 10^{-8} M, 10^{-9} M). It showed that Icariside II increased the phosphorylation of eNOS-Ser1177 in a dose-dependent manner, and reached the peak at the concentration of 10^{-6} M. On the other hand, the level of p-eNOS^Ser1177 in 10^{-8} M and 10^{-9} M Icariside II-treated groups were not significantly different from that in the normal control group (Figs. 4A, 4C). Combined with the results of CCK-8, 10^{-6} M Icariside II was selected as the experimental concentration for subsequent experiments in this study.
Figure 4  Effect of Icariside II on the dose- and time-dependent expression of p-eNOS^{Ser1177}. HUVECs were stimulated with Icariside II (10^{-5}M, 10^{-4}M, 10^{-3}M, 10^{-2}M, 10^{-1}M) for 1, 3, 5, 10, 15 min. (A) Western blot analysis of the expression of p-eNOS^{Ser1177} stimulated by different concentrations and time. (B) Quantitative analysis of total eNOS expression. (One-way ANOVA:* p < 0.05, ** p < 0.01, *** p < 0.001, experimental groups vs NC). Results are shown as one representative blot and as the mean ± SEM of quantified data from three independent experiments.

To determine the optimal time-point for eNOS-Ser1177 phosphorylation, 0, 1, 3, 5, 10, and 15 min were selected as the stimulation time of Icariside II. The results showed that the phosphorylation of eNOS-Ser1177 was significantly increased only 5 min after the treatment of Icariside II. Furthermore, the phosphorylation level of eNOS-Ser1177 gradually increased and reached a peak at 10 min (Figs. 4B, 4D). Therefore, 10 min was selected as the experimental time-point for subsequent experiments in this study.

To clarify the specific mechanism of eNOS-Ser1177 phosphorylation regulated via Icariside II, we explored the upstream signaling pathways such as PI3K/AKT/eNOS. The p-eNOS^{Ser1177} and p-eNOS^{Thr495} expression were significantly increased after Icariside II stimulation for 10 min, which was reversed by the use of PI3K inhibitor (LY294002) and AKT inhibitor (MK-2206) (Figs. 5A–5C). After stimulation of HUVECs with Icariside II (0, 1, 3, 5, 10, and 15 min), the expression of p-PI3K and p-AKT^{Ser473} were significantly upregulated and peaked at 10 min (Figs. 5D–5F). Then, AMPK, CaMKII, PKA, and PKC signaling pathways were also explored. The expression of p-eNOS^{Ser1177} was significantly increased in HUVECs treated with Icariside II for 10 min. The up-regulation was yet alleviated when treated with AMPK inhibitor (Dorsomorphin) and PKC inhibitor (Bisindolylmaleimide X). The phosphorylation of eNOS-Ser1177 in the Icariside II+CaMKII inhibitor (KN-62) group and the Icariside II+PKA inhibitor (H-89) group had no significant differences from Icariside II group (Figs. 6A, 6B). After treated with Icariside II alone (0, 1, 3, 5, 10, and 15 min), the expression of p-AMPK and p-PKC were significantly increased, in which p-AMPK peaked at 3 min and p-PKC peaked at 5 min (Figs.
Icariside II regulate the expression of p-eNOS\textsuperscript{Ser1177} via PI3K/AKT signaling pathway.

(A) Icariside II-induced eNOS-Ser1177 and AKT-Ser473 phosphorylation were abrogated by PI3K and AKT inhibitors (LY294002 and MK-2206) at 10 min. (B, C) Quantitative analysis of p-eNOS\textsuperscript{Ser1177} and p-AKT\textsuperscript{Ser473} expression. (One-way ANOVA: \( * p < 0.01, ** p < 0.001 \), experimental groups vs NC, ## \( p < 0.01, ### p < 0.001 \), experimental groups vs Icariside II group). (D) Western blot analysis of the expression of p-PI3K and p-AKT\textsuperscript{Ser473} stimulated by Icariside II. (D, E) Quantitative analysis of p-PI3K and p-AKT\textsuperscript{Ser473} expression. (One-way ANOVA: \( * p < 0.05, ** p < 0.01 \), experimental groups vs NC).

Results are shown as one representative blot and as the mean \( \pm \) SEM of quantified data from three independent experiments.

Figure 5

6C–6E). These results suggested that Icariside II rapidly regulated the phosphorylation of eNOS-Ser1177 by activating PI3K/AKT, AMPK, and PKC signaling pathways.

Icariside II rapidly induced eNOS-Thr495 dephosphorylation of HUVECs via PI3K/AKT and PKC signaling pathway

To study the effect of Icariside II on the phosphorylation of NOS-Thr495, HUVECs were stimulated with Icariside II (10\(^{-6}\) M) for 0, 1, 3, 5, 10, and 15 min. The expression level of p-eNOS\textsuperscript{Thr495} was higher in Icariside II treated group compared with the normal control group and peaked at 10 min (Figs. 7A, 7B). As a negative regulatory residue, the up-regulation of eNOS-Thr495 phosphorylation was often associated with the decrease of NO release which was not in accordance with the results above. To investigate whether Icariside II can impact the rapid dephosphorylation of eNOS-Thr495, Icariside II was applied for stimulating HUVECs for multiple durations (0, 0.5, 1, 1.5, 15, 30, 45, and 60 min). The results showed that the phosphorylation of eNOS-Thr495 was significantly
Figure 6  Icariside II regulate the expression of p-eNOS\textsuperscript{Ser1177} via AMPK and PKC signaling pathway. (A) Icariside II-induced eNOS-Ser1177 phosphorylation was abrogated by AMPK and PKC inhibitors (Bisindolylmaleimide X and Dorsomorphin), while CaMKII and PKA inhibitors (H-89 and KN-62) were not affected. (B) Quantitative analysis of p-eNOS\textsuperscript{Ser1177} expression. (One-way ANOVA: *\( p < 0.05, ** p < 0.01\), experimental groups vs NC, #*\( p < 0.05, ### p < 0.01\), experimental groups vs Icariside II group). (C) Western blot analysis of the expression of p-PI3K and p-AKT\textsuperscript{Ser473} stimulated by Icariside II. (D, E) Quantitative analysis of p-AMPK and p-PKC expression. (One-way ANOVA: *\( p < 0.05, *** p < 0.001\), experimental groups vs NC). Results are shown as one representative blot and as the mean ± SEM of quantified data from three independent experiments.

Icariside II did not influence eNOS-Ser113 phosphorylation

To research the effect of Icariside II on eNOS-Ser113 phosphorylation, time-points of Icariside II were chosen as the same as before (0, 1, 3, 5, 10, and 15 min). No significant
Figure 7  Effect of Icariside II on the expression of p-eNOS<sup>Ser1177</sup> via PI3K/AKT, AMPK, and PKC signaling pathways. (A, D, E) HUVECs were stimulated with Icariside II for 0.5, 1, 1.5, 3, 5, 10, 15, 30, 45 and 60 min. Western blot was used to analyze the expression of p-eNOS<sup>Thr495</sup>. (B, C, F) Quantitative analysis of p-eNOS<sup>Thr495</sup> expression. (One-way ANOVA: *p < 0.01, **p < 0.001, experimental groups vs NC). (G) Icariside II-induced eNOS-Thr495 dephosphorylation was abrogated by PI3K, AKT, and PKC inhibitors (LY-294002, MK-2206, and Dorsomorphin), while other inhibitors were not affected. (H) Quantitative analysis of p-eNOS<sup>Thr495</sup> expression. (One-way ANOVA: *p < 0.05, experimental groups vs NC, #p < 0.05, ##p < 0.01, experimental groups vs Icariside II group). Results are shown as one representative blot and as the mean ± SEM of quantified data from three independent experiments.
Figure 8  Effect of Icariside II on the expression of p-eNOS\textsuperscript{Ser113}. HUVECs were stimulated with Icariside II for 1, 3, 5, 10, and 15 min. Quantitative analysis of p-eNOS\textsuperscript{Ser113} expression. (One-way ANOVA:* \( p < 0.05 \), ** \( p < 0.01 \), *** \( p < 0.001 \), experimental groups vs NC). Results are shown as the mean ± SEM of quantified data from three independent experiments.

Song et al. (2022), PeerJ, DOI 10.7717/peerj.14192

... differences in the expression of p-eNOS\textsuperscript{Ser113} between Icariside II stimulated groups and the normal control groups (Fig. 8) In brief, the NO release of HUVECs might be affected by Icariside II via regulating the phosphorylation of eNOS-Ser1177 and eNOS-Thr495, not eNOS-Ser113.
DISCUSSION

It is well known that the NO released by eNOS is essential for endothelial cell function, which can be regulated by eNOS phosphorylation (Goshi, Zhou & He, 2019; Mount, Kemp & Power, 2007). Endothelial function is closely related to cardiovascular diseases, andrology diseases, kidney diseases, etc (Rajendran et al., 2013; Jourde-Chiche et al., 2019). In this paper, we found that Icariside II rapidly induced the phosphorylation of eNOS-Ser1177 and eNOS-Thr495 via multiple signaling pathways, and rapidly increased NO release in HUVECs, demonstrating the great potential of Icariside II in the treatment of multiple diseases (Fig. 9).

In this study, Icariside II was found to promote the eNOS-Ser1177 phosphorylation of HUVECs in 15 min. The phosphorylation of eNOS-Ser1177 may disrupt the autoinhibitory function of the eNOS carboxy-terminus, thereby rendering the activation of eNOS (Mount, Kemp & Power, 2007; Lane & Gross, 2002). In short, most stimulations that activate eNOS promote phosphorylation of the eNOS-Ser1177, including drugs (such as shenfu injection and atorvastatin) (Zhu et al., 2020; Manickavasagam et al., 2007), compounds (such as betulinic acid and Propionyl-l-carnitine) (Jin et al., 2016; Ning & Zhao, 2013), mechanical factors (Ghimire et al., 2019; Balligand, Feron & Dessy, 2009), and humoral factors (Pooja et al., 2018), and ultimately lead to increase NO synthesis. Li et al. (2015) indicated that Icariside II could increase p-eNOS\textsuperscript{Ser1177} expression of human cavernous endothelial cells down-regulated by high-glucose conditions in 4 days. Few studies researched the effect...
of Icariside II on eNOS-Ser1177 phosphorylation within a short time (less than 1 h). The phosphorylation of eNOS-Thr495 in the Ca2+/CaM binding domain could reduce the activity of eNOS and decrease the NO release of HUVECs (Mount, Kemp & Power, 2007). We found that Icariside II was able to increase the expression of p-eNOSThr495 within 30 min and decrease it at 45 min. Evidence suggested that dephosphorylation of eNOS-Thr495 was coordinated with the activation of eNOS-Ser1177 phosphorylation (Harris et al., 2001; Michell et al., 2001; Fleming et al., 2001; Peluso et al., 2018), while it had also been reports of the opposite result (Schmitt et al., 2009).

Notably, a significant increase in NO release of HUVECs was found after Icariside II stimulation for less than 60 min, which may be associated with rapidly up-regulated eNOS-Ser1177 phosphorylation. However, the increased eNOS-Thr495 phosphorylation was also observed during the same period of Icariside II stimulation (less than 30 min), which was inconsistent with the result of up-regulated NO release. It might be caused by the fact that the up-regulated phosphorylation of eNOS-Ser1177 played a dominant role and may override the negative effect of eNOS-Thr495 phosphorylation. In addition, although eNOS-Thr495 was indicated to be the negative regulatory residue, after mutation of eNOS-Thr495 to alanine and mimicking the dephosphorylation of eNOS-Thr495, Lin et al. (2003) found the occurrence of “uncoupling” eNOS, which was often associated with the down-regulation of the NO release. However, more research is needed to give more powerful evidence for these hypotheses, such as the measurement of ROS. Even so, we found significant dephosphorylation of eNOS-Thr495 at 45 min, which makes it easier to explain why the NO release in HUVECs was increased after Icariside II stimulation.

Different from eNOS-Ser1177 and eNOS-Thr495, only a handful of studies focused on eNOS-Ser113, phosphorylation of which was usually considered to inhibit the activation of eNOS. It was reported that cyclin-dependent kinase 5 was able to up-regulate eNOS-Ser113 phosphorylation, decrease eNOS dimer stability, and reduce NO release (Lee et al., 2010). However, Urano et al. (2008) found that angiopoietin-related growth factors could activate the ERK1/2 signaling pathway in HUVECs and increase the phosphorylation of eNOS-1177 and eNOS-Ser113, so as to up-regulate the production of NO. However, results in this study did not indicate a significant effect of Icariside II on eNOS-Ser113 phosphorylation. In short, the effect of Icariside II on eNOS phosphorylation is complex which promotes the NO release of HUVECs and demonstrates the potential of Icariside II to regulate endothelial function.

Although Icariside II stimulation was reported to increase the expression of total eNOS in endothelial cells at a late time (48 or 96 h) (Liu et al., 2011; Li et al., 2015), no changes in total eNOS were observed at an early time (less than 1 h in this study) which may be related to the insufficient time for eNOS transcription and translation.

In this study, the common upstream signaling pathways of eNOS phosphorylation were detected by western blot, including PI3K, AKT, AMPK, CaMKII, PKA, and PKC[21-25]. The results indicated that Icariside II was able to activate the eNOS-Ser1177 phosphorylation via PI3K/AKT, AMPK, and PKC significant pathways, and the eNOS-Thr495 dephosphorylation by PI3K/AKT, and PKC signaling pathways. PI3K/AKT and AMPK signaling pathways may be the positive regulator of eNOS which play an important
role in endothelial cell survival, mobilization, migration and homing (Chu et al., 2017; Rodríguez et al., 2021). It was reported that the activation of AMPK/PI3K/AKT signaling pathway could increase eNOS-Ser1177 phosphorylation and decrease eNOS-Thr495 phosphorylation (Xing et al., 2015). In this study, the activation of AMPK signaling pathway was not associated with the eNOS-Thr495 dephosphorylation. Signorello et al. (2009) suggested that homocysteine was able to stimulated the eNOS-Thr495 phosphorylation and the dephosphorylation of eNOS-Ser1177 by PKC activation which was inconsistent with the results in this study.

It was worth noting that the effect of Icariside II on eNOS phosphorylation was only researched in less than 1 h, the effect over a longer period needs to be explored in more experiments. It was reported that compound 21 and quercetin were also able to regulate the eNOS phosphorylation rapidly (Peluso et al., 2018; Li et al., 2012). Because of the short stimulation time (less than 15 min), the total signaling pathway proteins (Such as PI3K, AKT, AMPK, and PKC) were not detected in this study. Several signaling pathway inhibitors were applied in this study, some of which (such as dorsomorphin and LY294002) were often limited by off-target effects (Hao et al., 2010; Kumar et al., 2008). Further lines of research would be necessary to complete the data on the expression of the total signaling pathway proteins and to solve the problem of off-target effects of inhibitors. Flavonoids are widely distributed by plants and have multiple potential biological benefits, including regulating endothelial function, anti-inflammatory, anti-cancer, anti-fungal, etc (Zakaryan et al., 2017). As one of the active flavonoids, Icariside II can regulate eNOS phosphorylation rapidly which suggests that Icariside II may assist in the treatment of acute diseases (such as myocardial infarction and cerebral ischemia) and erectile dysfunction which has been preliminary explored in other in vivo and in vitro studies (Hu et al., 2020; Gao et al., 2020; Liu et al., 2020; Gu et al., 2021; Xu et al., 2015). Although this study provides important knowledge to the field of eNOS phosphorylation and the physiological and pharmacological effect of Icariside II, whether the results of our in vitro study are consistent with the in vivo situation still needs to be verified.

CONCLUSIONS

Our study found that Icariside II could regulate rapid phosphorylation of eNOS-Ser1177 and eNOS-Thr495 via multiple signaling pathways and promote the NO release of HUVECs, regulating endothelial function in a short time. It may provide a novel pharmacologic molecule to assist in the treatment of several diseases. More investigations are required to explore the therapeutic potential of Icariside II.

ACKNOWLEDGEMENTS

The authors are thankful for the excellent graphing tool provided by the website “Biorender” (https://biorender.com).
ADDITIONAL INFORMATION AND DECLARATIONS

Funding
This work was supported by the National Natural Science Foundation of China (Grant no. 81971379). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
National Natural Science Foundation of China: 81971379.

Competing Interests
The authors declare there are no competing interests.

Author Contributions
- Wenpeng Song conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Yiming Yuan performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Xiaohui Tan performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Yangyang Gu performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Jianyu Zeng conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.
- Weidong Song conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Zhongcheng Xin conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Dong Fang conceived and designed the experiments, performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Ruili Guan conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Data Availability
The following information was supplied regarding data availability:
The original images for blots and gels are available in the Supplementary File.

Supplemental Information
Supplemental information for this article can be found online at http://dx.doi.org/10.7717/peerj.14192#supplemental-information.
REFERENCES

Balligand JL, Feron O, Dessy C. 2009. eNOS activation by physical forces: from short-term regulation of contraction to chronic remodeling of cardiovascular tissues. *Physiological Reviews* 89(2):481–534 DOI 10.1152/physrev.00042.2007.

Bhang DH, Kim BJ, Kim BG, Schadler K, Baek KH, Kim YH, Hsiao W, Ding BS, Rafii S, Weiss MJ, Chou ST, Kolon TF, Ginsberg JP, Ryu BY, Ryem S. 2018. Testicular endothelial cells are a critical population in the germline stem cell niche. *Nature Communications* 9(1):4379 DOI 10.1038/s41467-018-06881-z.

Busse R, Fleming I. 1998. Pulsatile stretch and shear stress: physical stimuli determining the production of endothelium-derived relaxing factors. *Journal of Vascular Research* 35(2):73–84 DOI 10.1159/000025568.

Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE. 1999. AMP-activated protein kinase phosphorylation of endothelial NO synthase. *FEBS Letters* 443(3):285–289 DOI 10.1016/S0014-5793(98)01705-0.

Cheng J, Yang HL, Gu CJ, Liu YK, Shao J, Zhu R, He YY, Zhu XY, Li MQ. 2019. Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1/ROS/VEGF. *International Journal of Molecular Medicine* 43(2):945–955.

Chu P, Han G, Ahsan A, Sun Z, Liu S, Zhang Z, Sun B, Song Y, Lin Y, Peng J, Tang Z. 2017. Phosphocreatine protects endothelial cells from methylglyoxal induced oxidative stress and apoptosis via the regulation of PI3K/Akt/eNOS and NF-κB pathway. *Vascular Pharmacology* 91:26–35 DOI 10.1016/j.vph.2016.08.012.

Cyr AR, Huckaby LV, Shiva SS, Zuckerbraun BS. 2020. Nitric oxide and endothelial dysfunction. *Critical Care Clinics* 36(2):307–321 DOI 10.1016/j.ccc.2019.12.009.

Donato AJ, Magerko BR, Lawson JR, Durrant LA, Lesniewski KA, Seals DR. 2011. SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans. *The Journal of Physiology* 589(Pt 18):4545–4554 DOI 10.1113/jphysiol.2011.211219.

Fleming I, Fisslthaler B, Dimmeler S, Kemp BE, Busse R. 2001. Phosphorylation of Thr(495) regulates Ca(2+)/calmodulin-dependent endothelial nitric oxide synthase activity. *Circulation Research* 88(11):E68–E75.

Gao J, Long L, Xu F, Feng L, Liu Y, Shi J, Gong Q. 2020. Icariside II, a phosphodiesterase 5 inhibitor, attenuates cerebral ischaemia/reperfusion injury by inhibiting glycogen synthase kinase-3 β-mediated activation of autophagy. *British Journal of Pharmacology* 177(6):1434–1452 DOI 10.1111/bph.14912.

Garcia V, Gilani A, Shkolnik B, Pandey V, Zhang FF, Dakarapu R, Gandham SK, Reddy NR, Graves JP, Gruzdov A, Zeldin DC, Capdevila JH, Falck JR, Schwartzman ML. 2017. 20-HETE signals through g-protein-coupled receptor GPR75 (G(q)) to affect vascular function and trigger hypertension. *Circulation Research* 120(11):1776–1788 DOI 10.1161/CIRCRESAHA.116.310525.

Ghimire K, Zaric J, Alday-Parejo B, Seebach J, Bousquenaud M, Stalin J, Bieler G, Schnittler HJ, Rüegg C. 2019. MAGI1 mediates eNOS activation and NO
production in endothelial cells in response to fluid shear stress. Cells 8(5):388 DOI 10.3390/cells8050388.

Godo S, Sawada A, Saito H, Ikeda S, Enkhjargal B, Suzuki K, Tanaka S, Shimokawa H. 2016. Disruption of physiological balance between nitric oxide and endothelium-dependent hyperpolarization impairs cardiovascular homeostasis in mice. Arteriosclerosis, Thrombosis, and Vascular Biology 36(1):97–107 DOI 10.1161/ATVBAHA.115.306499.

Goshi E, Zhou G, He Q. 2019. Nitric oxide detection methods in vitro and in vivo. Medical Gas Research 9(4):192–207.

Gu SJ, Li M, Yuan YM, Xin ZC, Guan RL. 2021. A novel flavonoid derivative of icariside II improves erectile dysfunction in a rat model of cavernous nerve injury. Andrology 9(6):1893–1901 DOI 10.1111/andr.13065.

Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, Hopkins CR, Lindsey CW, Hong CC. 2010. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chemical Biology 5(2):245–253 DOI 10.1021/cb9002865.

Harris MB, Ju H, Venema VJ, Liang H, Zou R, Michell BJ, Chen ZP, Kemp BE, Venema RC. 2001. Reciprocal phosphorylation and regulation of endothelial nitric-oxide synthase in response to bradykinin stimulation. Journal of Biological Chemistry 276(19):16587–16591 DOI 10.1074/jbc.M100229200.

He C, Wang Z, Shi J. 2020. Pharmacological effects of icariin. Advances in Pharmacology 87:179–203 DOI 10.1016/bs.apha.2019.10.004.

Hebert C, Siavash K, Norris, N.G. Nikitakis H, Sauk JJ. 2005. Endostatin inhibits nitric oxide and diminishes VEGF and collagen XVIII in squamous carcinoma cells. International Journal of Cancer 114(2):195–201 DOI 10.1002/ijc.20692.

Heeringa P, van Goor Y, Itoh-Lindstrom N, Maeda RJ, Falk KJ, Assmann CG, Kallenberg H, Jennette JC. 2000. Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. The American Journal of Pathology 156(3):879–888 DOI 10.1016/S0002-9440(10)64957-7.

Heiss EH, Dirsch VM. 2014. Regulation of eNOS enzyme activity by posttranslational modification. Current Pharmaceutical Design 20(22):3503–3513 DOI 10.2174/13816128113196660745.

Hu D, Gu Y, Wu D, Zhang J, Li Q, Luo J, Li S, Yuan Z, Zhu B. 2020. Icariside II protects cardiomyocytes from hypoxia-induced injury by upregulating the miR75p/BTG2 axis and activating the PI3K/Akt signaling pathway. International Journal of Molecular Medicine 46(4):1453–1465 DOI 10.3892/ijmm.2020.4677.

Jin SW, Choi CY, Hwang YP, Kim HG, Kim SJ, Chung YC, Lee KJ, Jeong TC, Jeong HG. 2016. Betulinic acid increases eNOS phosphorylation and NO synthesis via the calcium-signaling pathway. Journal of Agricultural and Food Chemistry 64(4):785–791 DOI 10.1021/acs.jafc.5b05416.

Jones SP, Girod AJ, Palazzo DN, Granger MB, Grisham D, Jourd’Heuil PL, Huang WG, Lefer DJ. 1999. Myocardial ischemia-reperfusion injury is exacerbated in
absence of endothelial cell nitric oxide synthase. *American Journal of Physiology* **276**(5):H1567–H1573.

Jourde-Chiche N, Fakhouri F, Dou L, Bellien J, Burtey S, Frimat M, Jarrot PA, Kaplanski G, Le Quintrec M, Pernin V, Rigothier C, Sallée M, Fremeaux-Bacchi V, Guerrot D, Roumenina LT. 2019. Endothelium structure and function in kidney health and disease. *Nature Reviews Nephrology* **15**(2):87–108 DOI 10.1038/s41581-018-0098-z.

Khan M, Maryam A, Qazi JI, Ma T. 2015. Targeting apoptosis and multiple signaling pathways with icariside II in cancer cells. *International Journal of Biological Sciences* **11**(9):1100–1112 DOI 10.7150/ijbs.11595.

Kolluru GK, Siamwala JH, Chatterjee S. 2010. eNOS phosphorylation in health and disease. *Biochimie* **92**(9):1186–1198 DOI 10.1016/j.biochi.2010.03.020.

Konukoglu D, Uzun H. 2017. Endothelial dysfunction and hypertension. *Advances in Experimental Medicine and Biology* **956**:511–540.

Kumar N, Afeyan R, Kim HD, Lauffenburger DA. 2008. Multipathway model enables prediction of kinase inhibitor cross-talk effects on migration of Her2-overexpressing mammary epithelial cells. *Molecular Pharmacology* **73**(6):1668–1678 DOI 10.1124/mol.107.043794.

Lane P, Gross SS. 2002. Disabling a C-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular NO synthesis by diverse physiological stimuli. *Journal of Biological Chemistry* **277**(21):19087–19094 DOI 10.1074/jbc.M200258200.

Lee CH, Wei YW, Huang YT, Lin YT, Lee YC, Lee KH, Lu PJ. 2010. CDK5 phosphorylates eNOS at Ser-113 and regulates NO production. *Journal of Cellular Biochemistry* **110**(1):112–117.

Lee GH, Kim CY, Zheng C, Jin SW, Kim JY, Lee SY, Kim MY, Han EH, Hwang YP, Jeong HG. 2021. Rutaecarpine increases nitric oxide synthesis via eNOS phosphorylation by TRPV1-dependent CaMKII and CaMKK β/AMPK signaling pathway in human endothelial cells. *International Journal of Molecular Sciences* **22**(17):9407 DOI 10.3390/ijms22179407.

Lee JH, Parveen A, Do MH, Lim Y, Shim SH, Kim SY. 2018. Lespedeza cuneata protects the endothelial dysfunction via eNOS phosphorylation of PI3K/Akt signaling pathway in HUVECs. *Phytomedicine* **48**:1–9 DOI 10.1016/j.phymed.2018.05.005.

Li H, Xu Y, Guan R, Matheu M, Lei H, Tian W, Gao Z, Lin G, Guo Y, Xin Z, Song W. 2015. Icariside II prevents high-glucose-induced injury on human cavernous endothelial cells through Akt-eNOS signaling pathway. *Andrology* **3**(2):408–416 DOI 10.1111/andr.303.

Li PG, Sun L, Han X, Ling S, Gan WT, Xu JW. 2012. Quercetin induces rapid eNOS phosphorylation and vasodilation by an Akt-independent and PKA-dependent mechanism. *Pharmacy* **89**(3-4):220–228 DOI 10.1159/000337182.

Lin MI, Fulton D, Babbitt R, Fleming I, Busse R, Pritchard Jr KA, Sessa WC. 2003. Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates
the coupling of L-arginine metabolism to efficient nitric oxide production. *Journal of Biological Chemistry* **278**(45):44719–44726 DOI 10.1074/jbc.M302836200.

Liu MB, Wang W, Gao JM, Li F, Shi JS, Gong QH. 2020. Icariside II attenuates cerebral ischemia/reperfusion-induced blood-brain barrier dysfunction in rats via regulating the balance of MMP9/TIMP1. *Acta Pharmacologica Sinica* **41**(12):1547–1556 DOI 10.1038/s41401-020-0409-3.

Liu T, Qin XC, Li WR, Zhou F, Li GY, Xin H, Gong YQ, Xin ZC. 2011. Effects of icariin and icariside II on eNOS expression and NOS activity in porcine aorta endothelial cells. *Beijing Da Xue Xue Bao Yi Xue Ban* **43**(4):500–504.

Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ, Uretsky BF, Birnbaum Y. 2007. The cardioprotective effect of a statin and cilostazol combination: relationship to Akt and endothelial nitric oxide synthase activation. *Cardiovascular Drugs and Therapy* **21**(5):321–330 DOI 10.1007/s10557-007-6036-0.

Michell BJ, Chen Z, Tiganis T, Stapleton D, Katsis F, Power DA, Sim AT, Kemp BE. 2001. Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase. *Journal of Biological Chemistry* **276**(21):17625–17628 DOI 10.1074/jbc.C100122200.

Milkiewicz M, Hudlicka O, Brown MD, Silgram H. 2005. Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. *American Journal of Physiology-Heart and Circulatory Physiology* **289**(1):H336–H343 DOI 10.1152/ajpheart.01105.2004.

Mount PF, Kemp BE, Power DA. 2007. Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. *Journal of Molecular and Cellular Cardiology* **42**(2):271–279 DOI 10.1016/j.yjmcc.2006.05.023.

Ning WH, Zhao K. 2013. Propionyl-L-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases. *Vascular Pharmacology* **59**(3–4):76–82 DOI 10.1016/j.vph.2013.07.001.

Peluso AA, Bertelsen JB, Andersen K, Mortsensen TP, Hansen PB, Sumners C, Bader M, Santos RA, Steckelings UM. 2018. Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase. *Clinical Science* **132**(7):777–790 DOI 10.1042/CS20171598.

Pooja D, Ghosh K, Bhargava, Sethy NK. 2018. Post-translational modifications of eNOS augment nitric oxide availability and facilitates hypoxia adaptation in Ladakhi women. *Nitric Oxide* **78**:103–112 DOI 10.1016/j.niox.2018.06.003.

Popyhova EB, Stepanova DD, Lagutina TS, Kiriiazi TV, Ivanov AN. 2020. The role of diabetes in the onset and development of endothelial dysfunction. *Problemly Endokrinologii* **66**(1):47–55.

Rafii S, Shapiro F, Pettengell R, Ferris B, Nachman RL, Moore MA, Asch AS. 1995. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. *Blood* **86**(9):3353–3363 DOI 10.1182/blood.V86.9.3353.bloodjournal8693353.
Rajendran P, Rengarajan T, Thangavel J, Nishigaki Y, Sakthisekaran D, Sethi G, Nishigaki I. 2013. The vascular endothelium and human diseases. *International Journal of Biological Sciences* **9**(10):1057–1069 DOI 10.7150/ijbs.7502.

Raynaud CM, Butler JM, Halabi NM, Ahmad FS, Ahmed B, Rafii S, Rafii A. 2013. Endothelial cells provide a niche for placental hematopoietic stem/progenitor cell expansion through broad transcriptomic modification. *Stem Cell Research* **11**(3):1074–1090 DOI 10.1016/j.scr.2013.07.010.

Rodriguez C, Muñoz M, Contreras C, Prieto D. 2021. AMPK, metabolism, and vascular function. *FEBS Journal* **288**(12):3746–3771 DOI 10.1111/febs.15863.

Schmitt CA, Heiss EH, Aristei Y, Severin T, Dirsch VM. 2009. Norfuraneol dephosphorylates eNOS at threonine 495 and enhances eNOS activity in human endothelial cells. *Cardiovascular Research* **81**(4):750–757 DOI 10.1093/cvr/cvn326.

Shi Y, Vanhoutte PM. 2017. Macro- and microvascular endothelial dysfunction in diabetes. *Journal of Diabetes* **9**(5):434–449 DOI 10.1111/1753-0407.12521.

Signorello MG, Giacobbe E, Segantin A, Avigliano L, Sinigaglia F, Maccarrone M, Leoncini G. 2011. Activation of human platelets by 2-arachidonoylglycerol: role of PKC in NO/cGMP pathway modulation. *Current Neurovascular Research* **8**(3):200–209 DOI 10.2174/156720211796558041.

Signorello MG, Segantin A, Passalacqua M, Leoncini G. 2009. Homocysteine decreases platelet NO level via protein kinase C activation. *Nitric Oxide* **20**(2):104–113 DOI 10.1016/j.niox.2008.11.005.

Song WP, Gu SJ, Tan XH, Gu YY, Song WD, Zeng JY, Xin ZC, Guan RL. 2021. Proteomic analysis and miRNA profiling of human testicular endothelial cell-derived exosomes: the potential effects on spermatogenesis. *Asian Journal of Andrology* **24**(5):478–486 DOI 10.4103/aja202190.

Tan XH, Fang D, Xu YD, Nan TG, Song WP, Gu YY, Gu SJ, Yuan YM, Xin ZC, Zhou LQ, Guan RL, Li XS. 2021. Skimmed bovine milk-derived extracellular vesicles isolated via salting-out: characterizations and potential functions as nanocarriers. *Frontiers in Nutrition* **8**:769223 DOI 10.3389/fnut.2021.769223.

Urano T, Ito Y, Akao M, Sawa T, Miyata K, Tabata M, Morisada T, Hato T, Yano M, Kadomatsu T, Yasunaga K, Shibata R, Murohara T, Akaike T, Tanihara H, Suda T, Oike Y. 2008. Angiopoietin-related growth factor enhances blood flow via activation of the ERK1/2-eNOS-NO pathway in a mouse hind-limb ischemia model. *Arteriosclerosis, Thrombosis, and Vascular Biology* **28**(5):827–834 DOI 10.1161/ATVBAHA.107.149674.

Wu J, Huang Y, Zhang J, Xiang Z, Yang J. 2022. LncRNA CPhar mediates exercise-induced cardioprotection by promoting eNOS phosphorylation at Ser1177 via DDX17/P13K/Akt pathway after MI/RI. *International Journal of Cardiology* **350**:16 DOI 10.1016/j.ijcard.2021.12.040.
Xing SS, Yang XY, Zheng T, Li WJ, Wu D, Chi JY, Bian F, Bai XL, Wu GJ, Zhang YZ, Zhang CT, Zhang YH, Li YS, Jin S. 2015. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK/PI3K/Akt/eNOS pathway. *Vascular Pharmacology* 72:141–152 DOI 10.1016/j.vph.2015.07.004.

Xu F, Wu Q, Li L, Gong J, Huo R, Cui W. 2021. Icariside II: anticancer potential and molecular targets in solid cancers. *Frontiers in Pharmacology* 12:663776 DOI 10.3389/fphar.2021.663776.

Xu Y, Guan R, Lei H, Gao Z, Li H, Hui Y, Zhou F, Wang L, Lin G, Xin Z. 2015. Implications for differentiation of endogenous stem cells: therapeutic effect from icariside II on a rat model of postprostatectomy erectile dysfunction. *Stem Cells and Development* 24(6):747–755 DOI 10.1089/scd.2014.0380.

Zakaryan H, Arabyan E, Oo A, Zandi K. 2017. Flavonoids: promising natural compounds against viral infections. *Archives of Virology* 162(9):2539–2551 DOI 10.1007/s00705-017-3417-y.

Zhu J, Song W, Xu S, Ma Y, Wei B, Wang H, Hua S. 2020. Shenfu injection promotes vasodilation by enhancing eNOS activity through the PI3K/Akt signaling pathway in vitro. *Frontiers in Pharmacology* 11:121 DOI 10.3389/fphar.2020.00121.